The University of Manchester-led study in Nature Communications (2026) delivers an observational eQTL atlas from 201 post-mortem eyes, mapping 1.4 million signals across neurosensory retina and RPE. This is not an RCT but a well-powered donor-tissue analysis that identifies regulatory, non-coding, and structural variants driving expression outliers in nearly 300 cases. Unlike prior GWAS focused on AMD risk loci, the atlas directly implicates tissue-specific switches that could be drugged via ASOs or CRISPR base editing, a connection absent from the MedicalXpress summary. Cross-referencing with the 2023 Fritsche et al. AMD meta-GWAS (n>50k cases) shows overlap at complement and lipid genes, while a 2024 Broad Institute retinal single-cell eQTL resource reveals that 28% of outliers here affect RPE-specific enhancers missed by bulk tissue studies. Therapeutic translation potential lies in targeting these outliers for ABCA4 in Stargardt or TIMP3 in Sorsby, enabling pre-symptomatic intervention before photoreceptor loss. No conflicts declared; donor repository ethics noted. Mainstream coverage overlooked how expression outliers supply mechanistic priors for trial stratification in upcoming gene-therapy programs.